{
    "nctId": "NCT05056844",
    "briefTitle": "Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge",
    "officialTitle": "Contrast Enhanced Spectral Mammography (CESM) for the Evaluation of Pathologic Nipple Discharge: A Pilot Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 66,
    "primaryOutcomeMeasure": "Sensitivity of contrast enhancement of contrast enhanced spectral mammography (CESM)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women presenting to MDACC for the evaluation of PND as the main or accompanying symptom\n* Age 25-85 years\n* Willing to participate in the study and undergo an IV placement, able to undergo iodinated contrast injection, and able to provide informed consent\n\nExclusion Criteria:\n\n* Reported history of an allergic reaction to iodinated contrast\n* History of anaphylactic reaction to any substance in the absence of a prior history of uneventful administration of iodine-based IV contrast.\n* Renal insufficiency\n* Pregnancy or lactation within 6 months\n* Breast surgery affecting the symptomatic breast within prior 6 months, if it was located within 5 cm from the nipple\n* Breast biopsy of the symptomatic breast within the last 2 months, if it was located within 5 cm from the nipple\n* Breast MRI performed within 24 months before the patient presented with qualifying symptoms (MRI performed contemporarily with CEM for the evaluation of new symptoms is not an exclusion criterion).\n* Known breast cancer or active inflammatory process (such as abscess or mastitis) in the breast of concern",
    "sex": "FEMALE",
    "minimumAge": "25 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}